Bevacizumab, a recombinant humanized monoclonal antibody already employed in treating specific cancer types [36], exerts its anti-angiogenic effects by inhibiting the binding of vascular endothelial growth factor (VEGF) to its receptor. The gene discussed is VEGFA; the disease is cancer.